ArticleNeonatology2025
Neonatal Outcomes of the Intubation-Surfactant-Extubation versus Less Invasive Surfactant Administration Method: A National Cohort Study in Korea.
Article in Neonatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A novel double-lumen tracheal tube-assisted InSurE versus LISA in preterm infants with RDS: a multicenter randomized trial.Frontiers in pediatrics · 2026Trial
- Reply to the Letter by Ramakrishnan et al.: "Methodological Considerations in the Comparison of INSURE and LISA in Very Preterm Infants".Neonatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: This study aimed to compare the outcomes of intubation-surfactant-extubation (INSURE) and less invasive surfactant administration (LISA) in very preterm infants with respiratory distress syndrome.
methodsThis study included preterm infants born in South Korea at <32 weeks' gestation and registered in the Korean Neonatal Network database between January 2019 and December 2022. We analyzed and compared the ventilator support duration, mortality, and major morbidities before discharge from the neonatal intensive care unit treated with INSURE and LISA methods.
resultsA total of 1,112 infants who received surfactants via INSURE (n = 627) or LISA (n = 485) were included. No significant intergroup differences were observed in the duration of invasive ventilation, bronchopulmonary dysplasia (BPD), intraventricular hemorrhage, or mortality. However, infants in the LISA group had a lower risk of severe BPD (adjusted odds ratio [aOR], 0.514; 95% confidence interval [CI], 0.346-0.763; p = 0.001), severe BPD or death (aOR, 0.586; 95% CI, 0.402-0.854; p = 0.005), massive pulmonary hemorrhage (aOR, 0.314; 95% CI, 0.122-0.807; p = 0.014), patent ductus arteriosus (aOR, 0.67; 95% CI, 0.497-0.902; p = 0.008), and culture-proven sepsis (aOR, 0.607; 95% CI, 0.411-0.896; p = 0.012) than did those in the INSURE group.
conclusionAlthough LISA did not demonstrate a reduction in either the requirement for respiratory support or its duration compared to INSURE, it was associated with a decrease in severe BPD. These results imply that LISA provides substantial advantages for mitigating severe forms of neonatal morbidities. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.